32.14

0.50% -0.16

Alto Neuroscience Inc (ANRO)

Overview News Price History Discussions Forecast

Alto Neuroscience Inc stock is traded at $32.14, with a volume of 874.49K. It is down -0.50% in the last 24 hours and up +15.61% over the past month. Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Previous Close:

$32.30

Open:

$31.77

24h Volume:

874.49K

Relative Volume:

1.72

Market Cap:

$1.25B

Revenue:

Net Income/Loss:

$-74.31M

P/E Ratio:

-12.95

EPS:

-2.4817

Net Cash Flow:

$-62.86M

1W Performance:

+12.10%

1M Performance:

+15.61%

6M Performance:

+90.29%

1Y Performance:

+930.13%

1-Day Range:

$29.88

$32.29

1-Week Range:

$27.40

$33.67

52-Week Range:

$3.046

$33.67

Alto Neuroscience Inc Stock (ANRO) Company Profile

Name

Alto Neuroscience Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

773-255-5012

Address

650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

ANRO's Discussions on Twitter

Compare ANRO vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANRO Alto Neuroscience Inc	32.14	1.13B	0	-74.31M	-62.86M	-2.4817
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Nov-17-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Chardan Capital Markets	Buy
Oct-23-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Oct-23-24	Downgrade	Wedbush	Outperform → Neutral
Sep-03-24	Initiated	Wedbush	Outperform
Feb-27-24	Initiated	Jefferies	Buy
Feb-27-24	Initiated	Robert W. Baird	Outperform
Feb-27-24	Initiated	Stifel	Buy
Feb-27-24	Initiated	TD Cowen	Outperform
Feb-27-24	Initiated	William Blair	Outperform

View All

Alto Neuroscience Inc Stock (ANRO) Latest News

01:28 AM

Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - MarketBeat

01:28 AM

Aug 14, 2026

Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan

Aug 14, 2026

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan

Aug 14, 2026

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - simplywall.st

Aug 14, 2026

Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - MarketBeat

Aug 14, 2026

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside - TradingView

Aug 14, 2026

Sirenia Capital (ANRO) discloses 2.22M Alto Neuroscience shares under beneficial ownership - Stock Titan

Aug 14, 2026

BofA Adjusts Price Target on Alto Neuroscience to $37 From $33 - marketscreener.com

Aug 14, 2026

Aug 13, 2026

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT) - The Globe and Mail

Aug 13, 2026

Alto Neuroscience stock hits all-time high at 32.74 USD By Investing.com - Investing.com Australia

Aug 13, 2026

Alto Neuroscience stock hits all-time high at 32.74 USD - Investing.com

Aug 13, 2026

Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Aug 13, 2026

Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat - MarketBeat

Aug 13, 2026

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.11, Implies 27% Upside - TradingView

Aug 13, 2026

Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock - MarketBeat

Aug 13, 2026

Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat

Aug 13, 2026

Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews

Aug 13, 2026

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $36.89, Implies 26% Upside - TradingView

Aug 13, 2026

Aug 12, 2026

Alto Neuroscience Q2 EPS beats estimates; completes $100M financing - scanx.trade

Aug 12, 2026

Alto Neuroscience (NYSE:ANRO) Announces Quarterly Earnings Results - MarketBeat

Aug 12, 2026

Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges - Stock Titan

Aug 12, 2026

Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands - quiverquant.com

Aug 12, 2026

Alto Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026